Cephalon, Inc.

Ratan Venkatraman Bhat

Matthew S Miller

Robert Siman

Donna Bozyczko-Coyne

Patricia C Contreras

Sheryl L Meyer

A method for determining a concentration of IGF-I that defines a therapeutically effective dose of IGF-I, i.e., a dose that will provide a therapeutic response in the treatment of neurological disorders for which IGF-I is utilized (including peripheral neuropathy, diabetic neuropathy, post-polio syndrome, small fiber neuropathy, ALS, and MS) is described. The method comprises determining whether a particular dose of IGF-I causes a 1.5 fold or greater increase in the homeostatic concentration of plasma IGFBP-2 in a mammal that has previously received a defined dose of IGF-I. The method of the invention can also be used to determine whether or not biological tolerance has developed to a particular dose of IGF-I.

Diagnostic uses of IGFBP-2

Methods for the biochemical and immunohistochemical detection of cell apoptosis are described. The methods utilize the detection and measurement of polypeptide fragments generated during apoptosis. Conditions associated with apoptosis may be detected by the methods of this invention. Methods are also presented for the screening of potential therapeutic compounds which inhibit or stimulate apoptosis. Kits for detection of apoptosis and diagnosis of diseases are also provided.

Growing community of inventors

West Chester, PA, United States of America

Ratan Venkatraman Bhat